Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Clinical trial NCT05638594 · RECRUITING
Trial details
- NCT number
- NCT05638594
- Sponsor
- Shengjing Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-20
- Primary completion
- 2025-12-10
- Enrollment
- 236
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.